Detection of autoantibodies to survivin in cervical mucus from patients with human papillomavirus-associated cervical cancer and precursor lesions.
OBJECTIVE
To investigate the prevalence of mucosal autoantibodies to survivin in patients with human papillomavirus (HPV)-associated cervical cancer and precursor lesions.


METHODS
Cervical mucus from 117 HPV-associated cervical cancer, 102 high-grade squamous intraepithelial lesion (HSIL), 107 low-grade SIL (LSIL), and 80 normal controls were tested by ELISA using either full length recombinant survivin or survivin-derived peptides. Survivin expression in cervical tissue biopsies was studied by Western Blotting.


RESULTS
Cervical mucus from 33 cervical cancer (28.2%), 17 HSIL (16.6%), and 8 LSIL (7.4%) patients reacted with recombinant survivin. The IgA-class antibody response was significantly higher than that observed in the normal controls. The level of mucosal anti-survivin response was associated to the level and intensity of survivin expression in the different lesions. Finally, reactivity against a survivin Nt-derived peptide was found more frequently than reactivity against a Ct-derived peptide.


CONCLUSIONS
IgA-class autoantibodies against survivin are present in a substantial proportion of cervical mucus from patients with HPV-associated cervical cancer, and precursor lesions. Mucosal anti-survivin response is positively associated with the level of survivin expression and the grade of cervical lesion.
Jimenez
Lizbeth Gonzalez
LG
Department of Molecular Biology and Biotechnology, Institute of Biomedical Research, National University of Mexico, Circuito Escolar s/n, Ciudad Universitaria, Mexico City, CP 04510, Mexico.
Aguilar
Maria Cristina
MC
Monroy
Olga L
OL
Cruz-Talonia
Fernando
F
Cruz
Rosa M
RM
Huitron
Carlos
C
Rocha-Zavaleta
Leticia
L
D001323:Autoantibodies / Q000096:biosynthesis* / Q000276:immunology; D002582:Cervix Mucus / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005260:Female; D006801:Humans; D007070:Immunoglobulin A / Q000276:immunology; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins / Q000096:biosynthesis / Q000276:immunology*; D009363:Neoplasm Proteins / Q000096:biosynthesis / Q000276:immunology*; D027383:Papillomaviridae / Q000276:immunology*; D030361:Papillomavirus Infections / Q000150:complications / Q000276:immunology*; D011446:Prospective Studies; D000077022:Survivin; D002583:Uterine Cervical Neoplasms / Q000276:immunology* / Q000473:pathology / Q000821:virology; D002578:Uterine Cervical Dysplasia / Q000276:immunology* / Q000821:virology
D001323:Autoantibodies; C107489:BIRC5 protein, human; D007070:Immunoglobulin A; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D009363:Neoplasm Proteins; D000077022:Survivin